Legacy Pharmaceutical expands Losartan Potassium tablet recall

Legacy Pharmaceutical Packaging is expanding its earlier recall of Losartan Potassium tablets, a prescription medication used to treat high blood pressure and congestive heart failure, to include one additional lot.

The product contains trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a potential human carcinogen.

Legacy has not received any reports of adverse events to date.

The following four repackaged lots numbers (3 initial repackaged lot and 1 expanded repackaged lot) , are being recalled:

LEGACY NDC#	Name and Strength	Count	Legacy Lot #	Expiry
68645-494-54	Losartan Potassium Tablets USP 50 mg	30	180190	10/2020
68645-494-54	Losartan Potassium Tablets USP 50 mg	30	180191	10/2020
68645-494-54	Losartan Potassium Tablets USP 50 mg	30	181597	02/2021
68645-494-54	Losartan Potassium Tablets USP 50 mg	30	181598	02/2021

The product can be identified by checking the product name and repackaged lot number on the bottle containing these products.

The recalled product was distributed by pharmacies nationwide.

What to do

Legacy is notifying its customers in writing and is arranging/assisting for return of all recalled products to Inmar Pharmaceutical Services.

Instructions for returning recalled products are provided in the recall letter.

Consumers with questions may contact Inmar at (877) 538-8443, Monday – Friday, 9am – 5pm EST.